Whilst your educational background appears solid IMO it has no correlation to the operating of a business, whereas the BOD of IMU are eminently qualified to run such an entity,
Taking the 2 directors you have quoted as an example - Leslie Chong Ms Chong joined the Group from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in leading clinical and department development in oncology Paul Hooper Mr Hopper is founder and Executive Chairman since February 2021. Mr Hopper is also currently Executive Chairman at Imugene Limited (ASX: IMU), which he founded in October 2012 and Radiopharm Theranostics Limited (ASX: RAD), which he founded in 2021. In addition, Mr. Hopper was also previously Chairman at Viralytics Limited (ASX:VLA) until it was acquired by Merck in 2018. He was previously Executive Chairman of Arovella Therapeutics (ASX: PTX) between May 2019 and June 2022, as well as a director of Prescient Therapeutics Limited (ASX: PTX) from May 2014 to January 2020. Mr Hopper brings 20 years of experience in the management and funding of biotechnology and healthcare companies in Australia and the United States.
V
IMU Price at posting:
4.0¢ Sentiment: Hold Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)